Filovirus emergence and vaccine development: A perspective for health care practitioners in travel medicine
- 1 July 2010
- journal article
- case report
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 9 (3) , 126-134
- https://doi.org/10.1016/j.tmaid.2010.05.003
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adultsVaccine, 2010
- Isolation of Genetically Diverse Marburg Viruses from Egyptian Fruit BatsPLoS Pathogens, 2009
- Single-Injection Vaccine Protects Nonhuman Primates against Infection with Marburg Virus and Three Species of Ebola VirusJournal of Virology, 2009
- Vesicular Stomatitis Virus-Based Ebola Vaccine Is Well-Tolerated and Protects Immunocompromised Nonhuman PrimatesPLoS Pathogens, 2008
- Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challengeVirology, 2008
- Recombinant Vesicular Stomatitis Virus Vector Mediates Postexposure Protection against Sudan Ebola Hemorrhagic Fever in Nonhuman PrimatesJournal of Virology, 2008
- Vaccine To Confer to Nonhuman Primates Complete Protection against Multistrain Ebola and Marburg Virus InfectionsClinical and Vaccine Immunology, 2008
- Recombinant Human Activated Protein C for the Postexposure Treatment of Ebola Hemorrhagic FeverThe Journal of Infectious Diseases, 2007
- A DNA Vaccine for Ebola Virus Is Safe and Immunogenic in a Phase I Clinical TrialClinical and Vaccine Immunology, 2006
- Laboratory Diagnostic Systems for Ebola and Marburg Hemorrhagic Fevers Developed with Recombinant ProteinsClinical and Vaccine Immunology, 2006